No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy

Panagiotis Baliakas; Mattias Mattsson; Anastasia Hadzidimitriou; Eva Minga; Andreas Agathangelidis; Lesley Ann Sutton; Lydia Scarfo; Zadie Davis; Xiao Jie Yan; Karla Plevova; Yorick Sandberg; Fie J. Vojdeman; Tatiana Tzenou; Charles C. Chu; Silvio Veronese; Larry Mansouri; Karin E. Smedby; Véronique Giudicelli; Florence Nguyen-Khac; Panagiotis Panagiotidis; Gunnar Juliusson; Achilles Anagnostopoulos; Marie Paule Lefranc; Livio Trentin; Mark Catherwood; Marco Montillo; Carsten U. Niemann; Anton W. Langerak; Sarka Pospisilova; Niki Stavroyianni; Nicholas Chiorazzi; David Oscier; Diane F. Jelinek; Tait Shanafelt; Nikos Darzentas; Chrysoula Belessi; Frederic Davi; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos

doi:10.3324/haematol.2017.182634

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy

Panagiotis Baliakas, Mattias Mattsson, Anastasia Hadzidimitriou, Eva Minga, Andreas Agathangelidis, Lesley Ann Sutton, Lydia Scarfo, Zadie Davis, Xiao Jie Yan, Karla Plevova, Yorick Sandberg, Fie J. Vojdeman, Tatiana Tzenou, Charles C. Chu, Silvio Veronese, Larry Mansouri, Karin E. Smedby, Véronique Giudicelli, Florence Nguyen-Khac, Panagiotis PanagiotidisGunnar Juliusson, Achilles Anagnostopoulos, Marie Paule Lefranc, Livio Trentin, Mark Catherwood, Marco Montillo, Carsten U. Niemann, Anton W. Langerak, Sarka Pospisilova, Niki Stavroyianni, Nicholas Chiorazzi, David Oscier, Diane F. Jelinek, Tait Shanafelt, Nikos Darzentas, Chrysoula Belessi, Frederic Davi, Paolo Ghia, Richard Rosenquist, Kostas Stamatopoulos

Research output: Contribution to journal › Letter › peer-review

11 Scopus citations

Original language	English (US)
Pages (from-to)	e158-e161
Journal	Haematologica
Volume	103
Issue number	4
DOIs	https://doi.org/10.3324/haematol.2017.182634
State	Published - Mar 23 2018

ASJC Scopus subject areas

Hematology

Access to Document

10.3324/haematol.2017.182634

Cite this

Baliakas, P., Mattsson, M., Hadzidimitriou, A., Minga, E., Agathangelidis, A., Sutton, L. A., Scarfo, L., Davis, Z., Yan, X. J., Plevova, K., Sandberg, Y., Vojdeman, F. J., Tzenou, T., Chu, C. C., Veronese, S., Mansouri, L., Smedby, K. E., Giudicelli, V., Nguyen-Khac, F., ... Stamatopoulos, K. (2018). No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy. Haematologica, 103(4), e158-e161. https://doi.org/10.3324/haematol.2017.182634

Baliakas, P, Mattsson, M, Hadzidimitriou, A, Minga, E, Agathangelidis, A, Sutton, LA, Scarfo, L, Davis, Z, Yan, XJ, Plevova, K, Sandberg, Y, Vojdeman, FJ, Tzenou, T, Chu, CC, Veronese, S, Mansouri, L, Smedby, KE, Giudicelli, V, Nguyen-Khac, F, Panagiotidis, P, Juliusson, G, Anagnostopoulos, A, Lefranc, MP, Trentin, L, Catherwood, M, Montillo, M, Niemann, CU, Langerak, AW, Pospisilova, S, Stavroyianni, N, Chiorazzi, N, Oscier, D, Jelinek, DF, Shanafelt, T, Darzentas, N, Belessi, C, Davi, F, Ghia, P, Rosenquist, R & Stamatopoulos, K 2018, 'No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy', Haematologica, vol. 103, no. 4, pp. e158-e161. https://doi.org/10.3324/haematol.2017.182634

@article{3ade62b737a94005a67f675c815c62f5,

title = "No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy",

author = "Panagiotis Baliakas and Mattias Mattsson and Anastasia Hadzidimitriou and Eva Minga and Andreas Agathangelidis and Sutton, {Lesley Ann} and Lydia Scarfo and Zadie Davis and Yan, {Xiao Jie} and Karla Plevova and Yorick Sandberg and Vojdeman, {Fie J.} and Tatiana Tzenou and Chu, {Charles C.} and Silvio Veronese and Larry Mansouri and Smedby, {Karin E.} and V{\'e}ronique Giudicelli and Florence Nguyen-Khac and Panagiotis Panagiotidis and Gunnar Juliusson and Achilles Anagnostopoulos and Lefranc, {Marie Paule} and Livio Trentin and Mark Catherwood and Marco Montillo and Niemann, {Carsten U.} and Langerak, {Anton W.} and Sarka Pospisilova and Niki Stavroyianni and Nicholas Chiorazzi and David Oscier and Jelinek, {Diane F.} and Tait Shanafelt and Nikos Darzentas and Chrysoula Belessi and Frederic Davi and Paolo Ghia and Richard Rosenquist and Kostas Stamatopoulos",

note = "Funding Information: this work was supported in part by the Swedish Cancer Society, the Swedish Research Council, the Lion{\textquoteright}s Cancer Research Foundation, the Marcus B{\"o}rgstr{\"o}m Foundation and Selander{\textquoteright}s Foundation, Uppsala; H2020 “AEGLE, An analytics framework for integrated and personalized healthcare services in Europe” by the EU; H2020 “MEDGENET, Medical Genomics and Epigenomics Network” (No.692298) by the EU; GCH-CLL: funded by the General Secretariat for Research and Technology (GSRT) of Greece and the Italian Ministry of Health (MoH); IMI2 “HARMONY”, funded by the EU; project CEITEC 2020 (LQ1601) by MEYS-CZ, project AZV-MH-CZ 15-30015A-4/2015. Funding Information: 1Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden;2Department of Hematology, Uppsala University Hospital, Sweden;3Institute of Applied Biosciences, Thessaloniki, Greece;4Universit{\`a} Vita-Salute San Raffaele, Milan; 5Strategic Research Program in CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; 6Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK;7The Feinstein Institute for Medical Research, Northwell Health, New York, USA;8CEITEC-Central European Institute of Technology, MasarykBrno, Czech Republic;9University Hospital Brno, Czech Republic;10Department of Immunology, Erasmus MC, University Medical Center Rotterdam, the Netherlands; 11Department of Hematology, Rigshospitalet, Copenhagen, Denmark; 12First Department of Propaedeutic Medicine, University of Athens, Greece;13Molecular Pathology Unit and Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy; 14Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, and Hematology Center, Karolinska University Hospital, Stockholm, Sweden;15IMGT{\textregistered}, the international ImMunoGeneTics information system{\textregistered}, Universit{\'e} de Montpellier, Laboratoire d{\textquoteright}ImmunoG{\'e}n{\'e}tique Mol{\'e}culaire LIGM, Institut de G{\'e}n{\'e}tique Humaine IGH, UPR CNRS 1142, Montpellier, France; 16Hematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France;17Lund University and Hospital Department of Hematology, Lund Stem Cell Center, Sweden; 18Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece;19Department of Medicine, Hematology and Clinical Immunology Branch, Padova University School of Medicine, Italy;20Venetian Institute of Molecular Medicine, Padova, Italy; 21Department of Hemato-Oncology, Belfast City Hospital, Belfast, UK;22Department of Immunology, Mayo Clinic, Rochester, MV, USA;23Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;24Hematology Department, Nikea General Hospital, Piraeus, Greece and 25Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden Correspondence: kostas.stamatopoulos@gmail.com doi:10.3324/haematol.2017.182634 Funding: this work was supported in part by the Swedish Cancer Society, the Swedish Research Council, the Lion{\textquoteright}s Cancer Research Foundation, the Marcus B{\"o}rgstr{\"o}m Foundation and Selander{\textquoteright}s Foundation, Uppsala; H2020 “AEGLE, An analytics framework for integrated and personalized healthcare services in Europe” by the EU; H2020 “MEDGENET, Medical Genomics and Epigenomics Network” (No.692298) by the EU; GCH-CLL: funded by the General Secretariat for Research and Technology (GSRT) of Greece and the Italian Ministry of Health (MoH); IMI2 “HARMONY”, funded by the EU; project CEITEC 2020 (LQ1601) by MEYS-CZ, project AZV-MH-CZ 15-30015A-4/2015.",

year = "2018",

month = mar,

day = "23",

doi = "10.3324/haematol.2017.182634",

language = "English (US)",

volume = "103",

pages = "e158--e161",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "4",

}

TY - JOUR

T1 - No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy

AU - Baliakas, Panagiotis

AU - Mattsson, Mattias

AU - Hadzidimitriou, Anastasia

AU - Minga, Eva

AU - Agathangelidis, Andreas

AU - Sutton, Lesley Ann

AU - Scarfo, Lydia

AU - Davis, Zadie

AU - Yan, Xiao Jie

AU - Plevova, Karla

AU - Sandberg, Yorick

AU - Vojdeman, Fie J.

AU - Tzenou, Tatiana

AU - Chu, Charles C.

AU - Veronese, Silvio

AU - Mansouri, Larry

AU - Smedby, Karin E.

AU - Giudicelli, Véronique

AU - Nguyen-Khac, Florence

AU - Panagiotidis, Panagiotis

AU - Juliusson, Gunnar

AU - Anagnostopoulos, Achilles

AU - Lefranc, Marie Paule

AU - Trentin, Livio

AU - Catherwood, Mark

AU - Montillo, Marco

AU - Niemann, Carsten U.

AU - Langerak, Anton W.

AU - Pospisilova, Sarka

AU - Stavroyianni, Niki

AU - Chiorazzi, Nicholas

AU - Oscier, David

AU - Jelinek, Diane F.

AU - Shanafelt, Tait

AU - Darzentas, Nikos

AU - Belessi, Chrysoula

AU - Davi, Frederic

AU - Ghia, Paolo

AU - Rosenquist, Richard

AU - Stamatopoulos, Kostas

N1 - Funding Information: this work was supported in part by the Swedish Cancer Society, the Swedish Research Council, the Lion’s Cancer Research Foundation, the Marcus Börgström Foundation and Selander’s Foundation, Uppsala; H2020 “AEGLE, An analytics framework for integrated and personalized healthcare services in Europe” by the EU; H2020 “MEDGENET, Medical Genomics and Epigenomics Network” (No.692298) by the EU; GCH-CLL: funded by the General Secretariat for Research and Technology (GSRT) of Greece and the Italian Ministry of Health (MoH); IMI2 “HARMONY”, funded by the EU; project CEITEC 2020 (LQ1601) by MEYS-CZ, project AZV-MH-CZ 15-30015A-4/2015. Funding Information: 1Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden;2Department of Hematology, Uppsala University Hospital, Sweden;3Institute of Applied Biosciences, Thessaloniki, Greece;4Università Vita-Salute San Raffaele, Milan; 5Strategic Research Program in CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy; 6Department of Haematology, Royal Bournemouth Hospital, Bournemouth, UK;7The Feinstein Institute for Medical Research, Northwell Health, New York, USA;8CEITEC-Central European Institute of Technology, MasarykBrno, Czech Republic;9University Hospital Brno, Czech Republic;10Department of Immunology, Erasmus MC, University Medical Center Rotterdam, the Netherlands; 11Department of Hematology, Rigshospitalet, Copenhagen, Denmark; 12First Department of Propaedeutic Medicine, University of Athens, Greece;13Molecular Pathology Unit and Haematology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy; 14Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, and Hematology Center, Karolinska University Hospital, Stockholm, Sweden;15IMGT®, the international ImMunoGeneTics information system®, Université de Montpellier, Laboratoire d’ImmunoGénétique Moléculaire LIGM, Institut de Génétique Humaine IGH, UPR CNRS 1142, Montpellier, France; 16Hematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France;17Lund University and Hospital Department of Hematology, Lund Stem Cell Center, Sweden; 18Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece;19Department of Medicine, Hematology and Clinical Immunology Branch, Padova University School of Medicine, Italy;20Venetian Institute of Molecular Medicine, Padova, Italy; 21Department of Hemato-Oncology, Belfast City Hospital, Belfast, UK;22Department of Immunology, Mayo Clinic, Rochester, MV, USA;23Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA;24Hematology Department, Nikea General Hospital, Piraeus, Greece and 25Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden Correspondence: kostas.stamatopoulos@gmail.com doi:10.3324/haematol.2017.182634 Funding: this work was supported in part by the Swedish Cancer Society, the Swedish Research Council, the Lion’s Cancer Research Foundation, the Marcus Börgström Foundation and Selander’s Foundation, Uppsala; H2020 “AEGLE, An analytics framework for integrated and personalized healthcare services in Europe” by the EU; H2020 “MEDGENET, Medical Genomics and Epigenomics Network” (No.692298) by the EU; GCH-CLL: funded by the General Secretariat for Research and Technology (GSRT) of Greece and the Italian Ministry of Health (MoH); IMI2 “HARMONY”, funded by the EU; project CEITEC 2020 (LQ1601) by MEYS-CZ, project AZV-MH-CZ 15-30015A-4/2015.

PY - 2018/3/23

Y1 - 2018/3/23

UR - http://www.scopus.com/inward/record.url?scp=85044414469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044414469&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.182634

DO - 10.3324/haematol.2017.182634

M3 - Letter

C2 - 29269523

AN - SCOPUS:85044414469

SN - 0390-6078

VL - 103

SP - e158-e161

JO - Haematologica

JF - Haematologica

IS - 4

ER -

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this